Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets

June 1, 2026 08:31 AM EDT DealsPharma Servi­er signs $1.55B up­front deal for Edge­wise's mus­cu­lar dy­s­tro­phy as­sets Kyle LaHucik Biotech Correspondent Servi­er will pick up the mus­cu­lar dy­s­tro­phy busi­ness from Edge­wise Ther­a­peu­tics for $1.55 bil­lion up­front, giv­ing the French phar­ma com­pa­ny ac­cess to an ex­per­i­men­tal neu­ro­mus­cu­lar … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER